These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38335730)
21. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820 [TBL] [Abstract][Full Text] [Related]
22. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209 [TBL] [Abstract][Full Text] [Related]
23. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC. Chen Y; Zhang C; Jin S; Li J; Dai J; Zhang Z; Guo R J Cell Mol Med; 2023 Jul; 27(14):2032-2044. PubMed ID: 37278440 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320 [TBL] [Abstract][Full Text] [Related]
25. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334 [TBL] [Abstract][Full Text] [Related]
29. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer. Huang HN; Hung PF; Chen YP; Lee CH Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651 [TBL] [Abstract][Full Text] [Related]
30. Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. Fujiwara R; Taniguchi Y; Rai S; Iwata Y; Fujii A; Fujimoto K; Kumode T; Serizawa K; Morita Y; Espinoza JL; Tanaka H; Hanamoto H; Matsumura I Biochem Biophys Res Commun; 2022 Oct; 626():156-166. PubMed ID: 35994825 [TBL] [Abstract][Full Text] [Related]
31. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441 [TBL] [Abstract][Full Text] [Related]
32. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Togashi Y; Hayashi H; Nakagawa K; Nishio K Drug Des Devel Ther; 2014; 8():1037-46. PubMed ID: 25114510 [TBL] [Abstract][Full Text] [Related]
33. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer. Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242 [TBL] [Abstract][Full Text] [Related]
34. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867 [TBL] [Abstract][Full Text] [Related]
35. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160 [TBL] [Abstract][Full Text] [Related]
36. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151 [TBL] [Abstract][Full Text] [Related]
37. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Murphy M; Stordal B Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938 [TBL] [Abstract][Full Text] [Related]